Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 5,911 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: mRI Clear all
Terminated Phase 4 Interventional Results available

Ultrasound Evaluation of Crohn's Disease

NCT03235180
View directory record Official record
Conditions
Crohn Disease
Interventions
Sulfur Hexafluoride, Ultrasound Elastography, Ultrasound Vascularity, Magnetic Resonance Enterography (MRE)
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Nov 6, 2026, 2:49 PM EST
Recruiting No phase listed Observational

Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry

NCT04536103
View directory record Official record
Conditions
Bone Diseases, Infectious, Musculoskeletal Diseases, Joint Diseases, Osteoarthritis, ACL Tear, Cartilage Degeneration
Interventions
MRI
Diagnostic Test
Lead sponsor
Xiaojuan Li
Other
Eligibility
18 Years to 50 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 6, 2026, 2:49 PM EST
Completed Not applicable Interventional

Cervical Nodal Mets in Squamous Cell Carcinoma of H&N - MRI, FDG-PET, & Histopathologic Correlation

NCT00313027
View directory record Official record
Conditions
Head and Neck Cancer, Carcinoma, Squamous Cell, Head and Neck Cancers
Interventions
PET scan
Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2012 · Synced Nov 6, 2026, 2:49 PM EST
Terminated Early Phase 1 Interventional

Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients

NCT04213794
View directory record Official record
Conditions
Malignant Abdominal Neoplasm, Malignant Pelvic Neoplasm, Recurrent Colon Carcinoma, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Gastric Carcinoma, Recurrent Liposarcoma, Recurrent Malignant Mesothelioma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Rectal Carcinoma, Recurrent Rhabdomyosarcoma, Recurrent Sarcoma, Refractory Colon Carcinoma, Refractory Desmoplastic Small Round Cell Tumor, Refractory Fallopian Tube Carcinoma, Refractory Gastric Carcinoma, Refractory Liposarcoma, Refractory Malignant Mesothelioma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma, Refractory Rectal Carcinoma, Refractory Rhabdomyosarcoma, Refractory Sarcoma, Resectable Liposarcoma, Resectable Malignant Mesothelioma, Resectable Sarcoma
Interventions
Cisplatin, Cytoreductive Surgery, Doxorubicin, Hyperthermic Intraperitoneal Chemotherapy, Sodium Thiosulfate, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Biospecimen Collection
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
1 Year to 25 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Nov 6, 2026, 2:49 PM EST
Completed Phase 2 Interventional Results available

Substance P Antagonist in the Treatment of Posttraumatic Stress Disorder

NCT00383786
View directory record Official record
Conditions
PTSD
Interventions
NK1 Antagoist (GR205171), Psychophysiology (Trauma Script), Psychophysiology (Verbal Threat), Psychophysiology (Fear Conditioning), Psychophysiology (Affective Modulation), Psychophysiology (Heart rate variability), Lumbar Puncture, 24-hour plasma sampling, MRI
Drug · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Nov 6, 2026, 2:49 PM EST
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Neuroimaging the Effects of Intravenous Anesthetic on Amygdala Dependent Memory Processes

NCT00504894
View directory record Official record
Conditions
Healthy
Interventions
Placebo, Propofol, Thiopental
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Nov 6, 2026, 2:49 PM EST
Active, not recruiting Not applicable Interventional

Quantitative Ultrasound (RS85 and R20) for Liver Fat Quantification in MASLD Using MRI-PDFF as Reference

NCT07192159
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease, Hepatic Steatosis, Liver Disease Parenchymal
Interventions
Quantitative ultrasound (DeepUSFF)
Device
Lead sponsor
Seoul National University Hospital
Other
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boardman, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 6, 2026, 2:49 PM EST
Suspended Phase 2 Interventional

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

NCT06200103
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Clinical Observation, Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, Questionnaire Administration, Single Photon Emission Computed Tomography
Procedure · Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Nov 6, 2026, 2:49 PM EST
Terminated Phase 4 Interventional Results available

7T Magnetic Resonance Spectroscopy and Skeletal Muscle Biopsy Findings in Statin Associated Adverse Muscle Events

NCT04507373
View directory record Official record
Conditions
Muscle Cramp, Ache, Weakness, Muscle, Statin Adverse Reaction
Interventions
Simvastatin 40mg
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Nov 6, 2026, 2:49 PM EST
Completed Not applicable Interventional Results available

Image-guided Cryoablation of Head, Neck and Spine Tumors

NCT02085941
View directory record Official record
Conditions
Head and Neck Neoplasms, Malignant Neoplasm of Vertebral Column
Interventions
Cryoablation, Biopsy
Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Nov 6, 2026, 2:49 PM EST
Recruiting Phase 1 Interventional

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

NCT05422794
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Triple-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Nab-paclitaxel, Pembrolizumab
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Boston, Massachusetts • Mineola, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Nov 6, 2026, 2:49 PM EST
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Transcranial Ultrasonic Neuromodulation of Primary Visual Cortex and Primary Auditory Cortex in Humans

NCT07508722
View directory record Official record
Conditions
Healthy Volunteers, no Condition, Basic Science
Interventions
Transcranial Focused Ultrasound Stimulation, Electroencephalography, Magnetic Resonance Imaging
Device
Lead sponsor
Massachusetts Institute of Technology
Other
Eligibility
21 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Nov 6, 2026, 2:49 PM EST
Completed Early Phase 1 Interventional

Predicting Treatment Response to Memantine in Autism Using Magnetic Resonance Spectroscopy

NCT02811627
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Memantine, Magnetic Resonance Imaging
Drug · Device
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
16 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Nov 6, 2026, 2:49 PM EST
Completed No phase listed Observational Accepts healthy volunteers

AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MS

NCT00617383
View directory record Official record
Conditions
Multiple Sclerosis, Clinically Isolated Syndrome
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
10 Years to 45 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Nov 6, 2026, 2:49 PM EST
Withdrawn Not applicable Interventional

Effects of CRT Optimization as Assessed by Cardiac MR

NCT04763460
View directory record Official record
Conditions
Heart Failure, Systolic
Interventions
Programming of CRT device settings
Device
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Nov 6, 2026, 2:49 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Magnetic Resonance Imaging (MRI) and Decline of Aging Aviator Performance

NCT01120860
View directory record Official record
Conditions
Age-related Cognitive Decline
Interventions
MRI
Device
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
45 Years to 100 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2011
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Nov 6, 2026, 2:49 PM EST
Completed Phase 2 Interventional

FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression

NCT06620042
View directory record Official record
Conditions
Bipolar Depression, Treatment Resistant Bipolar Depression
Interventions
Ketamine, Functional magnetic resonance imaging (fMRI)
Drug · Other
Lead sponsor
Drew Cumming
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Cleveland, Ohio • Ohio City, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 6, 2026, 2:49 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Abnormal 3-D MRI Flow Patterns in Adolescents Patients With Bicuspid Aortic Valve

NCT00412386
View directory record Official record
Conditions
Congenital Heart Disease, Bicuspid Aortic Valve
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
10 Years to 18 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Nov 6, 2026, 2:49 PM EST
Terminated Not applicable Interventional Results available

ExAblate Treatment of Uterine Fibroids for Fertility Enhancement

NCT00730886
View directory record Official record
Conditions
Uterine Fibroids, With Unexplained Infertility
Interventions
ExAblate 2000, Myomectomy
Device · Procedure
Lead sponsor
InSightec
Industry
Eligibility
21 Years to 40 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
6
States / cities
Los Angeles, California • Smyrna, Georgia • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Nov 6, 2026, 2:49 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improving Human Cerebrovascular Function Using Acute Intermittent Hypoxia

NCT05164705
View directory record Official record
Conditions
Healthy Brain Perfusion
Interventions
Acute Intermittent Hypoxia, Sham Acute Intermittent Hypoxia
Other
Lead sponsor
Northwestern University
Other
Eligibility
21 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Nov 6, 2026, 2:49 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Pelvic Vein Quantitative Flow Characterization Using 2D and 4D Flow MRI

NCT06888024
View directory record Official record
Conditions
May-Thurner Syndrome, Iliac Venous Compression
Interventions
non-contrast enhanced abdomen and pelvis MRI
Procedure
Lead sponsor
Ningcheng Peter Li
Other
Eligibility
18 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 6, 2026, 2:49 PM EST
Recruiting Phase 2 Interventional

Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy

NCT07892027
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions
Axicabtagene Ciloleucel, Biospecimen Collection, Brexucabtagene Autoleucel, Computed Tomography, Cyclophosphamide, Fludarabine, Natalizumab, Positron Emission Tomography
Biological · Procedure · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 6, 2026, 2:49 PM EST
Active, not recruiting Not applicable Interventional

Patient-Specific Decision Aid System for Shared Decision Making About Breast Reconstruction

NCT05130580
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Enhanced Consultation, Standard of Care Consultation, Conventional Imaging, Educational Intervention, Questionnaire Administration
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 6, 2026, 2:49 PM EST
Recruiting Phase 2 Interventional

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

NCT06834373
View directory record Official record
Conditions
Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent ALK-Positive Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Intravascular Large B-Cell Lymphoma, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory ALK-Positive Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Intravascular Large B-Cell Lymphoma, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography, Golcadomide, Leukapheresis, Positron Emission Tomography, Rituximab
Procedure · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 6, 2026, 2:49 PM EST